Xpansion Interpreter is designed to findout the number and location of AGG interruptions associated with expansion of the Fragile X gene.

It also aids in better understanding of an individual’s risk of having a child with Fragile X syndrome.

Asuragen CEO Matt Winkler said the launch of Xpansion Interpreter builds upon Asuragen’s proven innovation in their breakthrough technology AmplideX, Asuragen’s current CGG repeat primed PCR research reagents.

"With the ability to clinically determine the number and location of AGG interruptions, the long-time problem of determining the stability of certain Fragile X alleles becomes more clear, creating opportunities to improve patient care," Winkler said.